Abattis Bioceuticals (Abattis Bioceuticals) Cash-to-Debt : 1.53 (As of Sep. 2019)

View and export this data going back to . Start your Free Trial

What is Abattis Bioceuticals Cash-to-Debt?

Cash to Debt Ratio measures the financial strength of a company. It is calculated as a company's cash, cash equivalents, and marketable securities divide by its debt. Abattis Bioceuticals's cash to debt ratio for the quarter that ended in Sep. 2019 was 1.53.

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. Here we can see, Abattis Bioceuticals could pay off its debt using the cash in hand for the quarter that ended in Sep. 2019.

The historical rank and industry rank for Abattis Bioceuticals's Cash-to-Debt or its related term are showing as below:

ATTBF's Cash-to-Debt is not ranked ^*
in the Drug Manufacturers industry.
Industry Median: 0.93
* Ranked among companies with meaningful Cash-to-Debt only.

Abattis Bioceuticals Cash-to-Debt Historical Data

The historical data trend for Abattis Bioceuticals's Cash-to-Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.

* Premium members only.

Abattis Bioceuticals Cash-to-Debt Chart

Abattis Bioceuticals Annual Data

Trend

Sep10

Sep11

Sep12

Sep13

Sep14

Sep15

Sep16

Sep17

Sep18

Sep19

Cash-to-Debt

Get a 7-Day Free Trial

No Debt

1.21

No Debt

1.53

Abattis Bioceuticals Quarterly Data
	Dec14	Mar15	Jun15	Sep15	Dec15	Mar16	Jun16	Sep16	Dec16	Mar17	Jun17	Sep17	Dec17	Mar18	Jun18	Sep18	Dec18	Mar19	Jun19	Sep19
Cash-to-Debt	Get a 7-Day Free Trial															No Debt	No Debt	No Debt	2.28	1.53

Competitive Comparison of Abattis Bioceuticals's Cash-to-Debt

For the Drug Manufacturers - Specialty & Generic subindustry, Abattis Bioceuticals's Cash-to-Debt, along with its competitors' market caps and Cash-to-Debt data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Abattis Bioceuticals's Cash-to-Debt Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Abattis Bioceuticals's Cash-to-Debt distribution charts can be found below:

* The bar in red indicates where Abattis Bioceuticals's Cash-to-Debt falls into.

Abattis Bioceuticals Cash-to-Debt Calculation

This is the ratio of a company's Cash, Cash Equivalents, Marketable Securities to its debt. The debt includes the Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation. This ratio measures the financial strength of a company. This ratio is updated quarterly.

Abattis Bioceuticals's Cash to Debt Ratio for the fiscal year that ended in Sep. 2019 is calculated as:

Cash to Debt Ratio	=	Cash, Cash Equivalents, Marketable Securities	/	Total Debt
	=	Cash, Cash Equivalents, Marketable Securities	/	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)
	=	1.814	/	(1.092	+	0.094)
	=	1.53

Abattis Bioceuticals's Cash to Debt Ratio for the quarter that ended in Sep. 2019 is calculated as:

Cash to Debt Ratio	=	Cash, Cash Equivalents, Marketable Securities	/	Total Debt
	=	Cash, Cash Equivalents, Marketable Securities	/	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)
	=	1.814	/	(1.092	+	0.094)
	=	1.53

Abattis Bioceuticals (OTCPK:ATTBF) Cash-to-Debt Explanation

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. If it is smaller than 1, it means the company has more debt than the cash in hands. In this case, it is important to look the the company's Interest Coverage. Ben Graham requires that a company must have an Interest Coverage of at least 5.

Abattis Bioceuticals Cash-to-Debt Related Terms

Thank you for viewing the detailed overview of Abattis Bioceuticals's Cash-to-Debt provided by GuruFocus.com. Please click on the following links to see related term pages.

Abattis Bioceuticals (Abattis Bioceuticals) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Abattis Bioceuticals Corp (OTCPK:ATTBF) » Definitions » Cash-to-Debt

Comparable Companies

Traded in Other Exchanges

N/A

Address

1200 - 625 Howe Street, Vancouver, BC, CAN, V6C 2M6

Website

http://www.abattis.com

Abattis Bioceuticals Corp is a Canadian life science and biotechnology company focuses on aggregating, integrating and investing in agricultural technologies and biotechnology services for the legal cannabis industry. It is primarily engaged in producing, licensing and marketing proprietary ingredients and formulas for use in the biopharma, nutraceutical, cosmetic and animal nutrition markets. The company is also engaged in growing, extraction, testing, propagation and online distribution.